Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial

185Citations
Citations of this article
132Readers
Mendeley users who have this article in their library.

Abstract

Purpose: The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question. Patients and Methods: Two hundred forty-four patients were randomly assigned after conservative breast surgery to receive 12 weeks of cyclophosphamide, doxorubicin, methotrexate, fluorouracil, and prednisone (CAMFP) before RT (CT-first) or after RT (RT-first). Median follow-up for surviving patients was 135 months. Results: There were no significant differences between the CT-first and RT-first arms in time to any event, distant metastasis, or death. Sites of first failure were also not significantly different. Conclusion: Among breast cancer patients treated with conservative surgery, there is no advantage to giving RT before adjuvant chemotherapy. However, this study does not have enough statistical power to rule out a clinically important survival benefit for either sequence. © 2005 by American Society of Clinical Oncology.

Cite

CITATION STYLE

APA

Bellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., … Recht, A. (2005). Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial. Journal of Clinical Oncology, 23(9), 1934–1940. https://doi.org/10.1200/JCO.2005.04.032

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free